CMO's Industry Roundup: Urolithin A, Fibermaxxing and Pharma's D2P Play

This episode of the Root Cause Medicine Podcast features host Dr. Kate Kresge, ND in conversation with Dr. Jeff Gladd, MD, Chief Medical Officer at Fullscript and an integrative primary care physician. Together, they unpack three timely topics for whole-person clinicians: emerging human data on urolithin A as a mitophagy-activating postbiotic that may support mitochondrial function and immune aging; how to help patients engage with the “fiber maxing” trend in a safe, sustainable way that supports metabolic health, GI function, and diet adherence; and a new industry survey showing that 94% of pharma leaders are running or exploring direct-to-patient (DTP) programs, with implications for GLP-1 therapy access, continuity of care, and the clinician’s central role in guiding treatment decisions. (Nature)